See more : Access Bio, Inc. (950130.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of Black Diamond Therapeutics, Inc. (BDTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Black Diamond Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Rheinmetall AG (RNMBY) Income Statement Analysis – Financial Results
- Solon Eiendom ASA (0MSG.L) Income Statement Analysis – Financial Results
- Medallia, Inc. (MDLA) Income Statement Analysis – Financial Results
- Eagle Bancorp Montana, Inc. (EBMT) Income Statement Analysis – Financial Results
- John Mattson Fastighetsföretagen AB (publ) (JOMA.ST) Income Statement Analysis – Financial Results
Black Diamond Therapeutics, Inc. (BDTX)
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 437.00K | 3.24M | 2.22M | 600.00K | 47.00K | 44.00K | 24.00K |
| Gross Profit | -437.00K | -3.24M | -2.22M | -600.00K | -47.00K | -44.00K | -24.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 59.35M | 64.44M | 96.83M | 48.21M | 21.75M | 6.95M | 3.45M |
| General & Administrative | 27.11M | 28.39M | 30.04M | 21.36M | 7.58M | 1.95M | 666.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.11M | 28.39M | 30.04M | 21.36M | 7.58M | 1.95M | 666.00K |
| Other Expenses | 0.00 | -354.00K | -2.19M | -1.72M | 6.00K | -16.00K | -6.00K |
| Operating Expenses | 86.46M | 92.83M | 126.87M | 69.57M | 29.33M | 8.90M | 4.12M |
| Cost & Expenses | 86.46M | 92.83M | 126.87M | 69.57M | 29.33M | 8.90M | 4.12M |
| Interest Income | 1.92M | 2.03M | 3.46M | 4.04M | 461.00K | 4.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 | 0.00 | 65.00K |
| Depreciation & Amortization | 437.00K | 3.24M | 2.22M | 600.00K | 47.00K | 44.00K | 24.00K |
| EBITDA | -86.02M | -92.32M | -126.67M | -66.65M | -29.29M | -8.89M | -4.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -86.46M | -92.83M | -126.87M | -69.57M | -8.90M | -8.90M | -4.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.02M | 1.66M | 1.28M | 2.32M | -5.93M | -27.00K | -483.00K |
| Income Before Tax | -82.44M | -88.92M | -125.60M | -67.25M | -35.26M | -8.93M | -4.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.40M | -2.39M | -1.78M | 5.89M | -27.00K | 59.00K |
| Net Income | -82.44M | -84.52M | -123.20M | -65.48M | -41.14M | -8.93M | -4.60M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.88 | -2.33 | -3.40 | -1.99 | -1.15 | -0.64 | -0.64 |
| EPS Diluted | -1.88 | -2.33 | -3.40 | -1.99 | -1.15 | -0.64 | -0.64 |
| Weighted Avg Shares Out | 43.95M | 36.33M | 36.19M | 32.91M | 35.91M | 13.95M | 7.20M |
| Weighted Avg Shares Out (Dil) | 43.95M | 36.33M | 36.19M | 32.91M | 35.91M | 13.95M | 7.20M |
The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO
Source: https://incomestatements.info
Category: Stock Reports